Brian Bernick - Dec 6, 2022 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Signature
/s/ Brian Bernick
Stock symbol
TXMD
Transactions as of
Dec 6, 2022
Transactions value $
-$6,621
Form type
4
Date filed
12/9/2022, 06:41 PM
Previous filing
Sep 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXMD Common Stock Options Exercise $0 +3.17K +161.58% $0.00 5.13K Dec 6, 2022 Direct F1
transaction TXMD Common Stock Sale -$4.6K -935 -18.24% $4.92 4.19K Dec 6, 2022 Direct F2, F3
transaction TXMD Common Stock Sale -$2.02K -320 -7.63% $6.31 3.87K Dec 9, 2022 Direct F2
holding TXMD Common Stock 35.1K Dec 6, 2022 See Footnote F4
holding TXMD Common Stock 60 Dec 6, 2022 See Footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Restricted Stock Units Options Exercise $0 -3.17K -23.14% $0.00 10.5K Dec 6, 2022 Common Stock 3.17K $0.00 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2 The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F4 The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The reporting person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F5 The reported securities are owned by the GP. As disclosed in Footnote 4 above, the reporting person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The reporting person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein.
F6 The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022.